Abstract:Lysine Specific Demethylase 1 (KDM1A / LSD1) regulates mitochondrial respiration and stabilizes HIF-1A (hypoxia-inducible factor 1A). HIF-1A modulates reactive oxygen species (ROS) levels by increasing cellular glucose uptake, glycolysis, and endogenous antioxidants. The role of KDM1A in cellular ROS response has not previously been described. We determined the role of KDM1A in regulating the ROS response and the utility of KDM1A inhibitors in combination with ROS-inducing cancer therapies. Our results show that KDM1A inhibition sensitized cells to oxidative stress and increased total cellular ROS, which was mitigated by treatment with the antioxidant N-acetyl cysteine. KDM1A inhibition decreased basal mitochondrial respiration and impaired induction of HIF-1A after ROS exposure. Overexpression of HIF-1A salvaged cells from KDM1A inhibition enhanced sensitivity to ROS. Thus we found that increased sensitivity of ROS after KDM1A inhibition was mediated by HIF-1A and depletion of endogenous glutathione. We also show that KDM1A-specific inhibitor bizine synergized with antioxidant-depleting therapies, buthionine sulfoximine, and auranofin in rhabdomyosarcoma cell lines (Rh28 and Rh30). In this study, we describe a novel role for KDM1A in regulating HIF-1A functions under oxidative stress and found that dual targeting of KDM1A and antioxidant systems may serve as an effective combination anticancer strategy.

What problem does this paper attempt to address?

The problem this paper attempts to address is the development of an effective anti-cancer strategy by simultaneously targeting KDM1A (lysine-specific demethylase 1) and the antioxidant system. Specifically, the researchers explored the role of KDM1A in regulating intracellular reactive oxygen species (ROS) levels and evaluated the potential anti-cancer effects of combining KDM1A inhibitors with ROS-inducing therapies. ### Main Research Questions: 1. **The role of KDM1A in cellular ROS response**: The researchers aimed to determine how KDM1A regulates intracellular ROS levels and its function under oxidative stress conditions. 2. **Anti-cancer potential of KDM1A inhibitors**: The researchers assessed whether KDM1A inhibitors (such as bizine) could increase cellular sensitivity to oxidative stress, thereby enhancing the effectiveness of anti-cancer treatments. 3. **Dual targeting of KDM1A and the antioxidant system**: The researchers tested the synergistic effects of combining KDM1A inhibitors with antioxidant system inhibitors (such as buthionine sulfoximine and auranofin) to find a more effective anti-cancer strategy. ### Research Background: - **ROS and cancer**: High ROS levels, redox imbalance, and dysregulation of redox signaling pathways are important characteristics of cancer. Cancer cells maintain ROS balance by increasing antioxidant capacity, thereby evading the harmful effects of excessive ROS. - **Function of KDM1A**: KDM1A influences cellular metabolism and redox state by regulating mitochondrial respiration and stabilizing HIF-1A (hypoxia-inducible factor 1α). HIF-1A regulates ROS levels by increasing cellular glucose uptake, glycolysis, and the production of endogenous antioxidants. ### Research Methods: - **Cell culture and treatment**: The researchers used various cell lines (such as HaCaT, FaDu, Rh28, and Rh30), inhibited KDM1A expression using chemical inhibitors (such as bizine and phenelzine) or siRNA knockdown, and then exposed the cells to hydrogen peroxide-induced oxidative stress. - **Cell viability and ROS measurement**: Cell viability assays and flow cytometry were used to detect total intracellular ROS levels and lipid peroxidation. - **Gene expression analysis**: Quantitative PCR was used to detect changes in the expression of ROS-responsive genes. - **Mitochondrial function analysis**: The Seahorse analyzer was used to assess mitochondrial oxygen consumption rate and ATP production. - **Combination with antioxidant system inhibitors**: The effects of combining KDM1A inhibitors with antioxidant system inhibitors (such as auranofin and buthionine sulfoximine) were tested. ### Main Findings: - **KDM1A inhibitors increase cellular sensitivity to oxidative stress**: KDM1A inhibitors (such as bizine) significantly increased cellular sensitivity to hydrogen peroxide-induced oxidative stress, as evidenced by decreased cell viability and increased ROS levels. - **KDM1A inhibitors act through HIF-1A-mediated mechanisms**: KDM1A inhibitors reduced the expression and activity of HIF-1A, leading to decreased cellular antioxidant capacity and increased ROS levels. - **Synergistic effects of antioxidant system inhibitors**: Combining KDM1A inhibitors with antioxidant system inhibitors (such as auranofin and buthionine sulfoximine) showed stronger anti-cancer effects. ### Conclusion: The research results indicate that KDM1A plays an important role in regulating cellular ROS levels. By simultaneously targeting KDM1A and the antioxidant system, the anti-cancer effects of ROS-inducing therapies can be significantly enhanced. This finding provides a theoretical basis for developing new anti-cancer strategies.

Dual targeting of KDM1A and antioxidants is an effective anticancer strategy

Targeting the ROS/PI3K/AKT/HIF‐1α/HK2 Axis of Breast Cancer Cells: Combined Administration of Polydatin and 2‐Deoxy‐d‐glucose

Targeting KDM1A Attenuates Wnt/β-catenin Signaling Pathway to Eliminate Sorafenib-Resistant Stem-Like Cells in Hepatocellular Carcinoma.

Abstract 376: Targeting the convergence on HIF-1α of CDK4/6 and MAPK pathway: Implications for enhanced anticancer strategies

Pharmacological inhibition of KDM5A for cancer treatment

α-Ketoglutarate supplementation and NAD+ modulation enhance metabolic rewiring and radiosensitization in SLC25A1 inhibited cancer cells

Concurrent loss of LKB1 and KEAP1 enhances SHMT-mediated antioxidant defence in KRAS-mutant lung cancer

Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response

Abstract 5821: Synergism of FAK and ROS1 Inhibitors in the Treatment of CDH1-deficient Cancers Mediated by FAK-YAP-TRX Signaling

De novo pyrimidine biosynthesis inhibition synergizes with BCL-X targeting in pancreatic cancer

Integration of signaling pathway and bromodomain and extra-terminal domain inhibition for the treatment of mutant Kirsten rat sarcoma viral oncogene homolog cancer

A novel MTORC2-AKT-ROS axis triggers mitofission and mitophagy-associated execution of colorectal cancer cells upon drug-induced activation of mutant KRAS

Multifaceted Effects of Kinase Inhibitors on Pancreatic Cancer Cells Reveals Pivotal Entities with Therapeutic Implications

KDM4B Histone Demethylase Inhibition Attenuates Tumorigenicity of Malignant Melanoma Cells by Overriding the p53‐Mediated Tumor Suppressor Pathway

Extracellular matrix detached cancer cells resist oxidative stress by increasing histone demethylase KDM6 activity

Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer

Mtor and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors.

The Glutaminase-1 Inhibitor 968 Enhances Dihydroartemisinin-Mediated Antitumor Efficacy In Hepatocellular Carcinoma Cells

Dual Inhibitions on Glucose/Glutamine Metabolisms for Nontoxic Pancreatic Cancer Therapy

An Inhibitor of KDM5 Demethylases Reduces Survival of Drug-Tolerant Cancer Cells.

Enhancing the efficacy of glycolytic blockade in cancer cells via RAD51 inhibition